Northwestern University Lead Academic Participating Site Supplement Year 2

摘要/摘要： 西北大学罗伯特·H·卢里综合癌症中心(LCC)具有悠久的NCTN历史 自1973年以来以经社理事会成员身份参加。目前，LCC基础设施支持参与 通过ECOG-ACRIN、SWOG、Alliance、NRG和COG进行的临床试验和辅助研究。获得认可 应计、参与和高水平的数据质量，LCC已被NCTN领导层选中 参与2015年、2016年和2017年的高性能现场计划(HPSI)，以支持我们的基础设施和 以使其能够继续参与NCTN试验。 2019年，西北大学被指定为领先的学术表演场地(LAPS)，在这一新的 角色继续显著增加患者参加NCTN试验，这两年都超过了计划的应计目标 一个圈内的机构。 通过继续展示重大科学成就和新举措，招募 优秀的高级教员和高效的初级教员，全面和集成的基础设施 监督癌症相关临床试验，LCC将继续扩大对NCTN试验的参与，提供 科学地领导关键的网络活动，增加机构间的合作和获得独特的 科学资源，以促进癌症干预。

Summary/Abstract: The Robert H. Lurie Comprehensive Cancer Center of Northwestern University (LCC) has a long history of NCTN participation with ECOG membership since 1973. Currently, the LCC infrastructure supports participation in clinical trials and ancillary studies through the ECOG-ACRIN, SWOG, Alliance, NRG and COG. Recognized for accrual, participation and high-level of data quality, the LCC has been selected by the NCTN leadership to participate in the High Performing Site Initiative (HPSI) in 2015, 2016 and 2017 to support our infrastructure and to enable continued participation in NCTN trials. In 2019, Northwestern University was designated as a Lead Academic Performing site (LAPS) and in this new role continues to significantly accrue patients to NCTN trials, exceeding planned accrual goals in both years as a LAPS institution. Through continued demonstration of significant scientific accomplishments and new initiatives, recruitment of accomplished senior faculty and productive junior faculty, comprehensive and integrated infrastructure for oversight of cancer-related clinical trials, LCC will continue to expand participation in NCTN trials, provide scientific leadership of key network activities, and increase inter-institutional collaborations and access to unique scientific resources, to advance cancer interventions.